JP2018138578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018138578A5 JP2018138578A5 JP2018079985A JP2018079985A JP2018138578A5 JP 2018138578 A5 JP2018138578 A5 JP 2018138578A5 JP 2018079985 A JP2018079985 A JP 2018079985A JP 2018079985 A JP2018079985 A JP 2018079985A JP 2018138578 A5 JP2018138578 A5 JP 2018138578A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- concentration
- composition according
- insulin
- citrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- 229940125396 insulin Drugs 0.000 claims description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 108010073961 Insulin Aspart Proteins 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 229960004717 insulin aspart Drugs 0.000 claims description 2
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical group CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 7
- 229920001993 poloxamer 188 Polymers 0.000 description 7
- 229940044519 poloxamer 188 Drugs 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 108010065920 Insulin Lispro Proteins 0.000 description 6
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 6
- 229960002068 insulin lispro Drugs 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 229940100630 metacresol Drugs 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101500025353 Homo sapiens Insulin A chain Proteins 0.000 description 1
- 101500025354 Homo sapiens Insulin B chain Proteins 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092407P | 2014-12-16 | 2014-12-16 | |
| US62/092,407 | 2014-12-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531725A Division JP6328855B2 (ja) | 2014-12-16 | 2015-12-09 | 即効型インスリン組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020214703A Division JP7159277B2 (ja) | 2014-12-16 | 2020-12-24 | 即効型インスリン組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018138578A JP2018138578A (ja) | 2018-09-06 |
| JP2018138578A5 true JP2018138578A5 (enExample) | 2019-08-15 |
| JP7093669B2 JP7093669B2 (ja) | 2022-06-30 |
Family
ID=55066806
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531725A Active JP6328855B2 (ja) | 2014-12-16 | 2015-12-09 | 即効型インスリン組成物 |
| JP2018079985A Active JP7093669B2 (ja) | 2014-12-16 | 2018-04-18 | 即効型インスリン組成物 |
| JP2020214703A Active JP7159277B2 (ja) | 2014-12-16 | 2020-12-24 | 即効型インスリン組成物 |
| JP2022163910A Pending JP2023011641A (ja) | 2014-12-16 | 2022-10-12 | 即効型インスリン組成物 |
| JP2024199464A Pending JP2025032126A (ja) | 2014-12-16 | 2024-11-15 | 即効型インスリン組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531725A Active JP6328855B2 (ja) | 2014-12-16 | 2015-12-09 | 即効型インスリン組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020214703A Active JP7159277B2 (ja) | 2014-12-16 | 2020-12-24 | 即効型インスリン組成物 |
| JP2022163910A Pending JP2023011641A (ja) | 2014-12-16 | 2022-10-12 | 即効型インスリン組成物 |
| JP2024199464A Pending JP2025032126A (ja) | 2014-12-16 | 2024-11-15 | 即効型インスリン組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9993555B2 (enExample) |
| EP (2) | EP3233108B1 (enExample) |
| JP (5) | JP6328855B2 (enExample) |
| AR (1) | AR102869A1 (enExample) |
| CY (1) | CY1125275T1 (enExample) |
| DK (1) | DK3233108T3 (enExample) |
| ES (1) | ES2911207T3 (enExample) |
| HR (1) | HRP20220692T1 (enExample) |
| HU (1) | HUE058764T2 (enExample) |
| LT (1) | LT3233108T (enExample) |
| MA (1) | MA41188B1 (enExample) |
| MD (1) | MD3233108T2 (enExample) |
| PL (1) | PL3233108T3 (enExample) |
| PT (1) | PT3233108T (enExample) |
| RS (1) | RS63174B1 (enExample) |
| SI (1) | SI3233108T1 (enExample) |
| TW (1) | TW201630622A (enExample) |
| WO (1) | WO2016100042A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| EP2919804B1 (fr) | 2012-11-13 | 2018-01-31 | Adocia | Formulation à action rapide d'insuline comprenant un composé anionique substitué |
| AR102869A1 (es) * | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
| JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| EP4265296A3 (en) | 2016-09-29 | 2023-12-20 | Arecor Limited | Pharmaceutical formulation comprising an insulin compound |
| ES2886837T3 (es) | 2016-12-16 | 2021-12-21 | Novo Nordisk As | Composiciones farmacéuticas que contienen insulina |
| WO2018153506A1 (en) * | 2017-02-22 | 2018-08-30 | Adocia | Fast-acting insulin composition comprising a citric acid salt |
| CN110582264B (zh) * | 2017-03-26 | 2022-11-11 | V·R·斯塔福德 | 眼睑皮肤状况的处理方法 |
| CA3065308C (en) * | 2017-06-01 | 2022-05-17 | Eli Lilly And Company | Rapid-acting insulin compositions |
| EP3773474B1 (en) | 2018-04-04 | 2026-01-07 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| JP7465813B2 (ja) * | 2018-04-04 | 2024-04-11 | アレコル リミテッド | インスリン化合物の送達のための医療用注入ポンプシステム |
| EP3773473B1 (en) * | 2018-04-04 | 2026-07-01 | Arecor Limited | MEDICAL INFUSION PUMP SYSTEM FOR ADMINISTRATING AN INSULIN COMPOUND |
| WO2019243627A1 (fr) | 2018-06-23 | 2019-12-26 | Adocia | Dispositif pour injecter une solution d'insuline(s) |
| FR3083985A1 (fr) | 2018-07-23 | 2020-01-24 | Adocia | Dispositif pour injecter une solution d'insuline(s) |
| AU2020235643B2 (en) * | 2019-03-14 | 2025-03-13 | Augusta University Research Institute, Inc. | Methods and compositions for supporting renal health |
| US10639328B1 (en) * | 2019-03-27 | 2020-05-05 | College Of William & Mary | Compositions and methods for reducing hyperglycemia and treating diabetes |
| US10799564B1 (en) | 2019-05-06 | 2020-10-13 | Baxter International Inc. | Insulin premix formulation and product, methods of preparing same, and methods of using same |
| CN114980860A (zh) * | 2019-09-17 | 2022-08-30 | 卡斯制药公司 | 皮下注射胰岛素制剂以及施用方法 |
| US11951186B2 (en) | 2019-10-25 | 2024-04-09 | Willow Laboratories, Inc. | Indicator compounds, devices comprising indicator compounds, and methods of making and using the same |
| IL296090A (en) * | 2020-03-02 | 2022-11-01 | Thermalin Inc | Compositions containing rapid-acting insulin analogues |
| GB202004814D0 (en) | 2020-04-01 | 2020-05-13 | Arecor Ltd | Novel formulations |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK116527B (da) | 1967-03-01 | 1970-01-19 | Nordisk Insulinlab | Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse. |
| EP0018609B1 (de) | 1979-04-30 | 1983-09-21 | Hoechst Aktiengesellschaft | Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung |
| FI78616C (fi) | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| US4839341A (en) * | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NO162160C (no) | 1987-01-09 | 1989-11-15 | Medi Cult As | Serumfritt vekstmedium, samt anvendelse derav. |
| ES2053723T3 (es) | 1987-02-25 | 1994-08-01 | Novo Nordisk As | Nuevos derivados de insulina. |
| US5716927A (en) | 1988-12-23 | 1998-02-10 | Novo Nordisk A/S | Insulin analogs having a modified B-chain |
| HUT56857A (en) | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| AUPO066096A0 (en) | 1996-06-26 | 1996-07-18 | Peptide Delivery Systems Pty Ltd | Oral delivery of peptides |
| DE69924232D1 (de) | 1998-01-09 | 2005-04-21 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
| JP2002535287A (ja) | 1999-01-26 | 2002-10-22 | イーライ・リリー・アンド・カンパニー | 単分散性６量体のアシル化されたインスリンアナログ製剤 |
| JP2003514014A (ja) | 1999-11-15 | 2003-04-15 | ティー ガンガル，ハナマラディ | 静脈注入のためのブドウ糖およびインスリン含有液体配合物 |
| JP4147234B2 (ja) | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、カートリッジ及び吐出装置 |
| US20020141946A1 (en) | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| JP4800959B2 (ja) * | 2003-11-13 | 2011-10-26 | ノヴォ ノルディスク アー／エス | 糖尿病及び過食症を治療するためのｇｌｐ−１ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物 |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| EP2106790B1 (en) | 2004-03-12 | 2012-10-24 | Biodel, Inc. | Rapid acting drug delivery compositions |
| US20070086952A1 (en) | 2005-09-29 | 2007-04-19 | Biodel, Inc. | Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
| US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| WO2007121256A2 (en) | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| US8084022B2 (en) | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008013955A2 (en) | 2006-07-27 | 2008-01-31 | Nektar Therapeutics | Sustained release formulations for pulmonary delivery |
| JP5552046B2 (ja) * | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | インスリン誘導体を含有する薬学的製剤 |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| FR2943538B1 (fr) * | 2009-03-27 | 2011-05-20 | Adocia | Formulation a action rapide d'insuline recombinante humaine |
| US20120094902A1 (en) | 2009-03-27 | 2012-04-19 | Adocia | Fast-acting insulin formulation |
| ES2543705T3 (es) | 2009-06-26 | 2015-08-21 | Novo Nordisk A/S | Preparación que contiene insulina, nicotinamida y arginina |
| CA2805031A1 (en) | 2010-07-07 | 2012-01-12 | Biodel, Inc. | Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin |
| EP2720712B1 (en) * | 2011-06-17 | 2016-03-02 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| US20130022592A1 (en) | 2011-06-17 | 2013-01-24 | Daniel Edward Vaughn | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme |
| US20130231281A1 (en) | 2011-11-02 | 2013-09-05 | Adocia | Rapid acting insulin formulation comprising an oligosaccharide |
| SG11201403714TA (en) | 2011-12-30 | 2014-07-30 | Halozyme Inc | Ph20 polypeptide variants, formulations and uses thereof |
| US9399065B2 (en) | 2012-04-16 | 2016-07-26 | Biodel Inc. | Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin |
| US9381247B2 (en) * | 2012-04-16 | 2016-07-05 | Biodel Inc. | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain |
| US20150174209A1 (en) | 2012-05-25 | 2015-06-25 | Amylin Pharmaceuticals. Llc | Insulin-pramlintide compositions and methods for making and using them |
| EP2919804B1 (fr) | 2012-11-13 | 2018-01-31 | Adocia | Formulation à action rapide d'insuline comprenant un composé anionique substitué |
| US20150065423A1 (en) | 2013-08-30 | 2015-03-05 | Perosphere, Inc. | Rapid acting injectable formulations |
| CA2936563A1 (en) | 2014-01-13 | 2015-07-16 | Thermalin Diabetes, Llc | Rapid action insulin formulations and pharmaceutical delivery systems |
| WO2015120457A1 (en) | 2014-02-10 | 2015-08-13 | Biodel Inc. | Stabilized ultra-rapid-acting insulin formulations |
| US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
| AR102869A1 (es) * | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
| JO3749B1 (ar) * | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
-
2015
- 2015-12-01 AR ARP150103921A patent/AR102869A1/es unknown
- 2015-12-01 TW TW104140209A patent/TW201630622A/zh unknown
- 2015-12-09 DK DK15817678.4T patent/DK3233108T3/da active
- 2015-12-09 HR HRP20220692TT patent/HRP20220692T1/hr unknown
- 2015-12-09 LT LTEPPCT/US2015/064744T patent/LT3233108T/lt unknown
- 2015-12-09 WO PCT/US2015/064744 patent/WO2016100042A1/en not_active Ceased
- 2015-12-09 RS RS20220416A patent/RS63174B1/sr unknown
- 2015-12-09 SI SI201531823T patent/SI3233108T1/sl unknown
- 2015-12-09 PL PL15817678T patent/PL3233108T3/pl unknown
- 2015-12-09 MA MA41188A patent/MA41188B1/fr unknown
- 2015-12-09 EP EP15817678.4A patent/EP3233108B1/en not_active Revoked
- 2015-12-09 HU HUE15817678A patent/HUE058764T2/hu unknown
- 2015-12-09 US US14/963,279 patent/US9993555B2/en active Active
- 2015-12-09 JP JP2017531725A patent/JP6328855B2/ja active Active
- 2015-12-09 ES ES15817678T patent/ES2911207T3/es active Active
- 2015-12-09 PT PT158176784T patent/PT3233108T/pt unknown
- 2015-12-09 EP EP22164140.0A patent/EP4108253A1/en active Pending
- 2015-12-09 MD MDE20170200T patent/MD3233108T2/ro unknown
-
2018
- 2018-04-18 JP JP2018079985A patent/JP7093669B2/ja active Active
- 2018-05-14 US US15/978,329 patent/US11123406B2/en active Active
-
2020
- 2020-12-24 JP JP2020214703A patent/JP7159277B2/ja active Active
-
2021
- 2021-09-17 US US17/478,747 patent/US11872266B2/en active Active
-
2022
- 2022-05-11 CY CY20221100329T patent/CY1125275T1/el unknown
- 2022-10-12 JP JP2022163910A patent/JP2023011641A/ja active Pending
-
2023
- 2023-12-14 US US18/540,193 patent/US12653866B2/en active Active
-
2024
- 2024-11-15 JP JP2024199464A patent/JP2025032126A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7159277B2 (ja) | 即効型インスリン組成物 | |
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| KR102327754B1 (ko) | 안정한 펩티드 제형물 및 제조 방법 | |
| KR102769685B1 (ko) | 양극성 용매에서 안정한 치료 제형들의 제조방법 | |
| MX2014012245A (es) | Composiciones de magnesio para modular la farmacocinetica y farmacodinamica de insulina y analogos de insulina, y el dolor en el sitio de inyeccion. | |
| JP2014518216A5 (enExample) | ||
| JP2012096063A (ja) | 医薬容器内の安定化した液体タンパク質の処方物 | |
| JP2010530846A (ja) | 高温で安定なペプチド製剤 | |
| JP2016539921A5 (enExample) | ||
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| CA2295140A1 (en) | Stable insulin formulations | |
| CZ234898A3 (cs) | Zdokonalené koncentrované injekční a infusní roztoky pro intravazální použití | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| CN107949374A (zh) | 稳定的胰高血糖素溶液 | |
| CN107106659B (zh) | 肠胃外胰高血糖素制剂 | |
| US20170312297A1 (en) | Long Acting Pharmaceutical Compositions For Hepatitis C | |
| JP2024543457A5 (enExample) | ||
| PE20252784A1 (es) | Composiciones y metodos para administrar paltusotina a pacientes con insuficiencia hepatica | |
| WO2026096588A1 (en) | Stabilized formulations of insulin and insulin analogs | |
| HK40070081B (en) | Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same | |
| IL312623A (en) | Preserved formulations | |
| RU2020109402A (ru) | Композиции на основе glp-1 и пути их применения | |
| CN110201148A (zh) | Prrt4细胞因子在制备治疗肝功能衰竭药剂中的应用 | |
| WO2003043537A1 (en) | Improvements in curing aids with tetrasilver tetroxide molecular crystal devices | |
| CN103655468A (zh) | 一种促胰岛素分泌肽融合蛋白Exendin-4-HSA溶液稳定制剂 |